PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q97391

Akio SUGIHARA, et al. Allowed: August 2, 2010

Appln. No.: 10/594,127 Group Art Unit: 1625

Confirmation No.: 8975 Examiner: Niloofar RAHMANI

Filed: September 25, 2006

For: COMPOSITION OF SOLIFENACIN OR SALT THEREOF FOR USE IN SOLID

FORMULATION

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP ISSUE FEE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

U.S. Appln. No.: 10/594,127

filing a request for continued examination (RCE) under \$1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

Attorney Docket No.: Q97391

foreign language documents, Applicant encloses herewith a copy of a Israeli Office Action

issued on August 10, 2010 in, in corresponding Israeli Patent Application No. 178249, together

with an English-language version of at least that portion of the Communication indicating the

degree of relevance found by the foreign patent office.

Applicant also notes that non-patent literature XP001061585, XP008061336 and

XP002500528 cited in the Israeli Office Action have previously been cited in an Information

Disclosure Statement submitted on December 10, 2008. Also patent WO 96/20194 and WO

03/103659 mentioned in the Israeli Office Action have previously been cited in an Information

Disclosure Statement submitted January 25, 2007.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

2

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98 U.S. Appln. No.: 10/594,127

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Attorney Docket No.: Q97391

 SUGHRUE MION, PLLC
 Jennifer M. Hayes

 Telephone: (202) 293-7060
 Registration No. 40,641

 Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550
65565
CUSTOMER NUMBER

Date: September 16, 2010